MRNS Stock Overview
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Marinus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.32 |
| 52 Week High | US$11.15 |
| 52 Week Low | US$3.47 |
| Beta | 1.11 |
| 1 Month Change | 4.80% |
| 3 Month Change | -1.15% |
| 1 Year Change | 57.99% |
| 3 Year Change | -53.14% |
| 5 Year Change | -65.10% |
| Change since IPO | -77.14% |
Recent News & Updates
Recent updates
Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?
Sep 22
Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S
Jun 12Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically
May 16Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts
Oct 26Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?
Oct 12Marinus Pharmaceuticals: Positive News Flow Of Note
Sep 22Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M
Aug 29Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher
Aug 13Marinus Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy
Jul 28Revisiting Marinus Pharmaceuticals
May 05Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues
Mar 27Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?
Mar 03Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption
Feb 28Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?
Nov 04Marinus Pharmaceuticals (MRNS) Investor Presentation - Slideshow
May 26We're Hopeful That Marinus Pharmaceuticals (NASDAQ:MRNS) Will Use Its Cash Wisely
Apr 14Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Intrinsic Value Is Potentially 53% Above Its Share Price
Mar 10Marinus Pharma's one late-stage ganaxolone study sufficient for US application for a type of epilepsy
Jan 13Is Marinus Pharmaceuticals (NASDAQ:MRNS) In A Good Position To Invest In Growth?
Jan 07
Shareholder Returns
| MRNS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 16.1% | -0.2% | 1.1% |
| 1Y | 58.0% | -4.5% | 11.7% |
Return vs Industry: MRNS exceeded the US Pharmaceuticals industry which returned -4.5% over the past year.
Return vs Market: MRNS exceeded the US Market which returned 11.7% over the past year.
Price Volatility
| MRNS volatility | |
|---|---|
| MRNS Average Weekly Movement | 12.0% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MRNS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: MRNS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 152 | Scott Braunstein | https://marinuspharma.com |
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.
Marinus Pharmaceuticals, Inc. Fundamentals Summary
| MRNS fundamental statistics | |
|---|---|
| Market Cap | US$399.21m |
| Earnings (TTM) | -US$133.61m |
| Revenue (TTM) | US$30.96m |
12.9x
P/S Ratio-3.0x
P/E RatioIs MRNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRNS income statement (TTM) | |
|---|---|
| Revenue | US$30.96m |
| Cost of Revenue | US$95.77m |
| Gross Profit | -US$64.81m |
| Other Expenses | US$68.80m |
| Earnings | -US$133.61m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.45 |
| Gross Margin | -209.32% |
| Net Profit Margin | -431.55% |
| Debt/Equity Ratio | 196.6% |
How did MRNS perform over the long term?
See historical performance and comparison